Publications


Refereed Journal Articles Only (No Abstracts, Conf Proceedings, etc)

2019


2019.67
Maserejian N, Bian S, Wang W, Jaeger J, Syrjanen J, Aakre J, Jack CR, Mielke M, Gao F. Practical algorithms to predict the probability of amyloid-β positivity in subjective cognitive decline or mild cognitive impairment possibly due to Alzheimer’s disease. Manuscript in preparation (May 2019)

2019.66
Amadoru S, Doré V, McLean C, Hinton F, Shepherd C, Halliday G, Leyton CE, Yates P, Hodges J, Masters CL, Villemagne VL, Rowe CC. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Submitted (April 2019)

2019.65
Masters CL. [Comment:] Electrode detects Aβ aggregates in Alzheimer’s plasma. https://www.alzforum.org/news/research-news/electrode-detects-av-aggregates-alzheimers-plasma (19 April 2019)

2019.64
Schultz SA, Doré V, Burnham SC, Bourgeat P, Mulligan RS, Bozinovski S, Fripp J, Ames D, Fowler C, Martins RN, Roberston J, Maruff P, Masters CL, Benzinger TLS, Villemagne VL and Rowe CC. Visually identified MK-6240-PET neurofibrillary tangle pattern subtypes are associated with distinct memory and cognitive performance. Manuscript in preparation (March 2019).

2019.63
Lim YY, Maruff P, Keneko N, Fowler C, Villemagne Vl, Kato T, Rowe CC, Arahata Y, Iwamoto S, Ito K, Tanaka K Yanagisawa K, Masters CL, Nakamura A. High performance plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease. Manuscript in preparation (March 2019)

2019.62
Baker JE, Bruns L, Hassenstab J, Masters CL, Maruff P. Modification and validation of a language learning model for neuropsychological studies of learning in older adults. Submitted (March 2019)

2019.61
van der Kall LM, Burnham SC, Doré V, Mulligan RS, Bozinovski S, Bourgeat P, Fripp J, Lim YY, Laws SM, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Roberston J, Maruff P, Masters CL, Villemagne VL and Rowe CC for the AIBL Research Group. Manuscript in preparation (March 2019)

2019.60
Doecke JD, Ward L, Burnham SC, Villemagne VL, Li Q-X, Collins S, Fowler CJ, Manuilova E, Widmann M, Rainey-Smith S, Masters CL. Elecsys® CSF biomarker immunoassays demonstrate concordance with results of amyloid-PET imaging in AIBL patient samples. Manuscript in preparation (February 2019)

2019.59
Lu Y-H, Wang Y-J. Nabs-Aβ. Manuscript in preparation. (February 2019)

2019.58
Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Doré V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O, for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Increased cerebral blood flow with increased amyloid burden in the preclinical phase of Alzheimer’s disease. Manuscript in preparation (January 2019)

2019.57
Mastwyk M, Barac AM, Radler M, Sgambellone R, Lowen VP, Mitchell N, Zisis G, Rowe CC, Masters CL. Science media – the best recruitment approach for a pre-clinical AD study. International Psychogeriatrics. Accepted (April 2019)

2019.56
Baker JE, Bruns Jr L, Hassenstab J, Masters CL, Maruff P, Lim YY. Validation of a repeated week-long associative learning task for estimating age-related impairments in rate of learning. Manuscript in preparation (January 2019)

2019.55
Frost S, Kanagasingam Y, Burnahm S, Koronyo-Hamaoui M, Koronyo Y, Biggs D, Czeszynski A, Black KL, Verdooner S, Cole G, Frautschy S, Ashfaq A, Bourgeat P Salvado O, Villemagne VL, Rowe CC, Macaulay L, Ames D, Masters CL, Taddei K, Rainey-Smith S, Martins RN, and the AIBL Research Group. Retinal autoflueorescence associated with Aβ-amyloid and Alzheimer’s disease. Manuscript in preparation (January 2019)

2019.54
Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham P, Fowler C, Bourgeat P, Li Q-X, Collins S, Bush AI, Rowe CC, Masters CL, Ames D, Hone E, Blennow K, Zetterberg H, Martins RN. CSF NfL concentration predicts brain atrophy and cognition in Alzheimer’s disease. Manuscript in preparation (April 2019)

2019.53
Xiong C, Luo J, Agboola S, Li Y, Albert M, Johnson SC, Koscik RL Masters CL, Soldan A, Villemagne VL, Li Q-X, McDade EM, Fagan AM, Massoumzadeh P, Benzinger T, Hassenstab J, Bateman RJ, Morris JC, the Dominantly Inherited Alzheimer Network. A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer disease from young adulthood and for designing prevention trials. Submitted (March 2019)

2019.52
Huq AJ, Fransquet P, Laws SN, Ryan J, Sebra R, Masters CL, Winship IM, James PA, Lacaze P. Genetic resilience to Alzheimer’s disease in APOE ε4 homozygotes: a systematic review. Alzheimer’s Dement. 2019; In Press (April 2019)

2019.51
Baker JE, Pietrzak RH, Laws SM, Ames D, Villemagne VL, Rowe CC, Masters CL, Maruff P, Lim YY, on behalf of the AIBL Research Group. Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. Neuropsychology. In Press (March 2019)

2019.50
Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, Papp KV, Doré V, Masters CL, Properzo MJ, Schultz AP, Johnson KA, Rentz DM, Sperling RA, Amariglio RE. Using subjective sognitive decline to identify high global amyloid in community-based samples: a cross-cohort study. Manuscript in preparation (November 2018)

2019.49
Fowler C, Roberston J, Rainey-Smith S, Ames D, Maruff P, Martins RN, Masters CL, Lautenschlager N, Rowe C, Salvado O, Savage G, Woodward M, Ellis KA, and the AIBL investigators. Diagnostic status, progression of cognitive decline, recruitment of new participants and retention of existing subjects at 36, 54 , 72 and 90 month follow up among 1112 initial participants in the Australian Imaging , Biomarkers and Lifestyle study (AIBL) and peer reviewed publications resulting from their participation: outputs from a decade–long highly productive cohort study. Manuscript in preparation (February 2019).

2019.48
Xu Y, Li W-W, Wang J, Shen Y-Y, Zeng G-H, Li H-I, Chen D-W, Fowler CI, Li Q-X, Masters CL, Zhou X-F, Wang Y-J. Neurotrophin receptor p75 mRNS levels in the white blood cells of patients with Alzheimer’s disease. Manuscript in preparation (September 2018).

2019.47
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens A, Barthel H, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based and MR-Less CapAIBL® approaches: Validation against histopathology. Alzheimer’s Dement. In Press (March 2019)

2019.46
Rowe CC, Amadoru S, Doré V, McLean C, Hinton F, Shepherd C, Halliday G, Leyton C, Hodges J, Masters CL, Villemagne VL. Correlation of amyloid PET expressed in Centiloid Units with neuropathological findings in Alzheimer’s disease. Manuscript in preparation (September 2018).

2019.45
Papp KV, Buckley R, Mormino E, Maruff P, Villemagne VL, Masters CL, Johnson KA, Rentz DM, Sperling RA, Amariglio RE, on behalf of collaborators from the Harvard Aging Brain Study, the Alzheimer’s Disease Neuroimaging Initiative and the Australia Imaging, Biomarker and Lifestyle study of aging. Clinical meaningfulness of short-term cognitive decline in normal older adults with elevated β-amyloid. Manuscript in preparation (October 2018).

2019.44
Vacher M, Porter T, Villemagne V, Milicic L, Peretti M, Fowler C, Rainey-Smith S, Ames D, Masters CL, Rowe C, Doecke J, Laws SM. Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition. Manuscript in preparation (December 2018).

2019.43
Burnham SC, Coloma PM, Li Q-X, Collins S, Savage G, Laws S, Doecke J, Maurff P, Martina RN, Ames D, Rowe CC, Masters CL, Villemagne VL. Application of the NIA-AA Research Framework: Towards a biological definition of Alzheimer’s disease using cerebrospinal fluid biomarkers in the AIBL study. Manuscript in preparation (November 2018)

2019.42
Lim WLF, Huynh K, Chatterjee P, Martins I, Jayawardana KS, Girls C, Mellet NA, Laws S, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, AIBL Research Group, Meikle PJ, Martins RN. Relationships between plasma lipids, risk factors and Alzheimer’s disease. Manuscript in preparation (July 2018)

2019.41
Huynh K, Lim WLF, Giles C, Jayawardana KS, Chatterjee P, Mellet NA, Martins I, Laws S, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters C, AIBL Research Group, Drew BG, Martins RN, Meikle PJ. Comprehensive targeted lipidomic profiles of prevalent and incident Alzheimer’s disease. Manuscript in preparation (July 2018)

2019.40
Quek Y-E, Lim YY, Harrington K, Dang C, Ames D, Laws S, Rainey-Smith S, Roberston J, Pietrzak RH, Snyder PJ, Villemagne VL, Rowe CC, Masters CL, Maruff P. β-Amyloid-related memory decline in preclinical Alzheimer’s disease is not associated with subjective or observed cognitive decline. Submitted. Archives of Clinical Neuropsychology. (July 2018)

2019.39
Dang C, Yassi N, Harrington KD, Lim YY, Ames D, Laws SM, Hickey M, Sohrabi HR, Xia Y, Doecke JD, Fripp J, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P for the AIBL Research Group. Examining resilience to age or amyloid β-associated cortical atrophy in SuperAging. Neurobiology of Aging. Accepted (October 2018)

2019.38
Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li Q-X, Rutz S, Widmann M, Leinenbach A, Blennow K. Method comparison study of the Elecsys® β-amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. Submitted to Clinica Chimica Acta. (April 2019).

2019.37
Bradfield NI, Ellis KA, Savage G, Maruff P, Burnham S, Darby D, Lautenschlager NT, Martins RN, Masters CL, Rainey-Smith SR, Roberston J, Rowe CC, Woodward M, Ames D. Breadth of baseline memory impairment in amnestic mild cognitive impairment predicts progression to Alzheimer’s disease dementia at 3 years. Manuscript in preparation (July 2018).

2019.36
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Peretti M, Sohrabi HR, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. SPON1 rs11023139 is associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal adults. Submitted (February 2019)

2019.35
Laffoon SB, Doecke JD, Roberts AM, Vance JA, Reeves BD, Pertile KK, Rumble RL, Fowler CJ, Trounson B, Ames D, Bush AI, Masters CL, Grieco PA, Dratz EA, Roberts BR, for the AIBL research group. Plasma protein biomarkers for Alzheimer’s disease that are dependent on sex and APOE genotype. Submitted (March 2019)

2019.34
Yassi N, Hilal S, Xia Y, Lim YY, Kuijf H, Fowler C, Yates P, Maruff P, Martins R, Ames D, Chen C, Rowe CC, Villemagne VL, Salvado O, Desmond PM, Masters CL. The influence of comorbidity of cerebrovascular disease and amyloid-β on Alzheimer’s disease. Submitted (April 2019)

2019.33
Eratne D, Loi SM, Walia N, Farrand S, Li Q-X, Varghese S, Walterfang M, Evans A, Mocellin R, Dhiman K, Gupta V, Malpas CB, Collins S, Masters CL, Velakoulis D. Utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders in younger people: a “C-reactive protein” for neurologists and psychiatrists? Under Review (April 2019)

2019.32
Lai M. The relationship between cognitive function and metabolic syndrome components combinations in adults at risk of cognitive deterioration.

2019.31
Lim YY, Maruff P, Masters CL, Sperling RA, Johnson KA, Mormino EC, on behalf of Alzheimer’s Disease Neuroimaging Initiative. Divergence of AV1451-PET and CSF tau measurements in preclinical and prodromal Alzheimer’s disease.

2019.31
Huq AJ, James PA, Lacaze P, Masters CL, Storey E, Winship IM. Genomic biomarkers of Alzheimer’s disease and other dementias: paving the path to precision diagnosis. (Submitted Jan 2018)

2019.30
Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman S, Chhatwal J, Danek A, Fagan AM, Ghetti B, Goate A, Graff-Radford N, Jucker M, Levin J, Marcus DS, Martins R, Masters CL, McCue L, McDade E, Mori H, Moulder KL, Noble JM, Paumier K, Preische O, Ringman J, Rossor M, Salloway S, Schofield P, Morris JC and the Dominantly Inherited Alzheimer Network. Similar rates of cognitive decline in autosomal dominant and sporadic Alzheimer disease. Submitted (March 2018)

2019.29
Sinclair B, Steward C, Venkatramen V, Aljondi R, Cox KL, Ellis KA, Ames D, Masters CL, Phal PM, Sharman MJ, Cyarto EV, Lautenschlager NT, Lai MM, Szoecke C, Desmond P. Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. Submitted (March 2017).

2019.28
Insel PS, Weiner MW, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff P, Hansson O, Mattsson N for the Alzheimer’s Disease Neuroimaging Initiative, the Australian Imaging, Biomarkers, and Lifestyle Study and the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Study. Determining clinically meaningful decline in preclinical Alzheimer’s disease. Neurology. In Press (April 2019)

2019.27
Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy J-P, Lesage F, Sylvestre J-P, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume M-A, Beaulieu S, Dirani M, Williamson R, Crowston JG, Nguyen CTO, Bui BV, van Wijngaarden P. Non-invasive, in vivo hyperspectral imaging identifies a retinal biomarker for Alzheimer’s disease. Submitted (April 2019)

2019.26
Hata S, Omori C, Kimura A, Saito H, Kimura N, Gupta V, Pedrini S, Hone E, Chatterjee P, Taddei K, Kasuha K, Ikeuchi T, Waragai M, Nishimura M, Hu A, Meijer L, Maeda M, Masters CL, Rowe C, Ames D, Martins RN, Yamamoto K, Suzuki T. Changes in p3-Alcβ40, products of Alcadein β generated by γ-secretase cleavages, in aged monkeys and Alzheimer’s disease patients. Submitted (August 2018)

2019.25
Bourgeat P, Villemagne VL, Dore V, Masters CL, Ames D, Rowe CC, Salvado O, Fripp J, for the AIBL Research Group and for the Alzheimer’s Disease Neuroimaging. PET-only 18F-AV1451 tau quantification. (Submitted ISBI conference 2017).

2019.24
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults. IBRO Reports. In press (May 2019)

2019.23
Harrington KD, Maruff P, Masters CL, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Cruchaga C, Morris JC, Hassenstab J. Undetected neuropathology biases estimates of cognitive aging in older adults. Submitted (April 2019)

2019.22
Jones A, Graham PL, Ames D, Ellis KA, Martins RN, Maruff P, Masters CL, Rowe CC, Villemagne VL, Savage G, and the AIBL research group. Memory profiling in the early detection of prodromal Alzheimer’s disease. Manuscript in preparation (February 2019)

2019.21
Pedrini S, Hone E, Gupta VB, Teimouri E, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Rainey-smith S, Verdile G, Sohrabi H, Taddei K, Martins I, Wilson AC, Laws SM, and Martins RN and the AIBL Research Group. Plasma high density lipoprotein fractions are altered in Alzheimer’s disease. (Submitted).

2019.20
Milicic L, Porter T, Gupta V, Burnham S, Lim YY, Doré V, Maruff P, Savage G, Peretti M, Bourgeat P, Ames D, Martins R, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Villemagne V, Laws SM. Genetic variation in CLU is associated with cognitive decline, hippocampal volume and short-term atrophy in preclinical Alzheimer’s disease. Alzheimers Res Ther. Submitted (March 2018)

2019.19
Xia Y, Yassi N, Bourgeat P, Raniga P, Desmond P, Fripp J, Villemagne V, Masters CL, Rowe C, Salvado. MRI based assessment of cerebrovascular pathology in Alzheimer’s disease. Paper presented at ISMRM-ESMRMB 2018, Paris. International Society for Magnetic Resonance in Medicine

2019.18
Huang X, Fowler C, Li QX, Perez KA, Drysdale C, Liu S, Bomke J, Trounson B, Barnham KJ, Wiley JS, Masters CL, Gu BJ. Identification of leukocyte surface biomarkers associated with progress of Alzheimer’s disease.

2019.17
Bransby L, Lim YY, Ames D, Fowler C, Robertson J, Harrington K, Snyder PJ, Villemagne VL, Salvado O, Masters CL, Maruff P, for the AIBL Research Group. Sensitivity of a preclinical Alzheimer’s cognitive composite (PACC) to amyloid β load in preclinical Alzheimer’s disease. J. Clin. Exp. Neuropsychol. In Press (March 2019)

2019.16
Gardener SL, Weinborn M, Sohrabi HR, Doecke J, Bourgeat P, Rainey-Smith SR, Shen K-K, Fripp J, Taddei K, Maruff P, Salvado O, Savage G, Ames D, Masters CL, Rowe CC, Martins RN, for the AIBL Research Group. Longitudinal trajectories in cortical thickness and volume atrophy; typical ageing versus cognitive super-ageing. Submitted (March 2019)

2019.15
Gu BJ, Huang X, Avula PK, Caruso E, Drysdale C, Vessey KA, Ou A, Fowler C, Liu T-H, Lin Y, Horton A, Masters CL, Wiley JS, Guymer RH and Fletcher EL. Deficits in monocyte function in age-related macular degeneration: a novel systemic change associated with early stages of the disease. Under revision (April 2019).

2019.14
Siddiqui MS, Francois M, Rainey-Smith S, Martins R, Masters CL, Ames D, Rowe CC, Macaulay SL, Fenech MF, Leifert WR, and the AIBL Research Group. DNA damage levels are increased in buccal cells from individuals with Alzheimer’s disease. Current Alzheimer Research. Under revision (February 2019)

2019.13
Roberts BR, Feng L, Fowler CJ, Roberts AM, Villemagne VL, Masters CL, Ryan TM and the AIBL research group. Elevated plasma levels of kallikrein-7 in individuals with prodromal Alzheimer’s disease. (Manuscript in preparation).

2019.12
Doecke JD, Perez-Grijlba V, Fandos N, Fowler C, Villemagne VL, Masters CL, Pesini P, Sarasa M, and the AIBL Research Group. Total Aβ42/40 ratio in plasma predict amyloid-PET status, independent of clinical AD diagnosis. Neurology (Submitted, January 2019)

2019.11
Venkatraman VK, Sanderson A, Cox KL, Ellis KA, Steward C. Phal PM, Gorelik G, Sharman MJ, Villemagne VL, Lai M, Cyarto EV, Merkel B, Ames D, Szoeke S, Rowe CC, Martins RN , Masters CL, Lautenschlager NT, Desmond PM. A two-year trial of the effect of physical activity on delaying progression of white matter hyperintensities and hippocampal loss in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial. (Submitted, December 2017).

2019.10
Burnham SC, Laws SM, Bugeon CA, Doré V, Porter T, Bourget P, Buckley RF, Murray K, Ellis KA, Salvado O , Ames D, Martins RN, Rentz D, Masters CL, Rowe CC, Villemagne VL, for the Alzheimer’s Disease Neuroimaging Initiative, and the AIBL Research Group. Estimating the age-related deposition of Aβ-amyloid deposition and the impact of APOEε4 carriage in Alzheimer’s disease. Submitted (March 2019)

2019.09
Franzmeier N, Ren J, Damm A, Monté-Runio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodriguez Gόmez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin K, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Gran S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee J-H, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MA, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M. The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease. Molec Psych. 2019; doi: 10.1038/s41380-019-0404-6

2019.08
Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alz Dem: Diagnosis, Assessment and Disease Monitoring. 2019; 11: 180-190.

2019.07
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. Klotho allele status is not associated Aβ and APOE ε4 related cognitive decline in preclinical Alzheimer’s disease. Neurobiology of Aging. 2019; 76: 162-165.

2019.06
Cox KL, Cyarto EV, Ellis KA, Ames D, Desmond P, Phal P, Sharman MJ, Szeoke C, Rowe CC, Masters CL, You E, Burrows S, Lai MMY, Lautenschlager NT. A randomized controlled trial of adherence to a 24-month home-based physical activity program and the health benefits for older adults at risk of Alzheimer’s disease: The AIBL Active-Study. J Alz Dis. 2019; doi: 10.3233/JAD-180521

2019.05
Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlson CM, Asthana S, Masters CL, Johnson S, Morris JC, Abert M, Gross AL. ATN profiles among cognitively normal individuals and lognitudinal cognitive outcomes. Neurol. 2019; doi: 10.1212/WNL.0000000000007248

2019.04
La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang J-H, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin L-W, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O’Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD. Multisite study of the relationships between the antemortem [11C]PiB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019; 15: 205-216.

2019.03
Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A. A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease. Sci Adv. 2019; 5: doi: 10.1126/sciadv.aau7220

2019.02
Taswell C, Donohue C, Mastwyk MT, Louey AG, Giummarra J, Robertson J, Darby DG, Masters CL, Rowe CC. Avoiding methodological bias in studies of amyloid imaging results disclosure. Alz Res Therapy. 2019; doi: 10.1186/s13195-019-0495-y

2019.01
Lothian A, Lago L, Mukherjee S, Fowler C, McLean CA, Horne M, Masters CL, Cappai R, Roberts BR. Characterisation of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn. Metallomics. 2019; 11: 128- 140.

2018


2018.46
Barnier AJ, Harris CB, Morris T, Savage G. Features of Successful and Unsuccessful Collaborative Memory Conversations in Long-Married Couples. Top Cogn Sci. 2018; 1-9.

2018.45
Barnier AJ, Harris CB, Morris T, Savage G. Collaborative facilitation in older couples: successful joint remembering across memory tasks. Front Psych. 2018; 9: 2385.

2018.44
Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Growth D, Verdile G, Villemagne VL, Laws SM. A polygenic risk score derived from episodic memory weighted genetic variants is associated with cognitive decline in preclinical Alzheimer’s disease. Frontiers in Aging Neuroscience. 2018; 10: 423.

2018.43
Harrington KD, Dang C, Lim YY, Ames D, Laws SM, Pietrzak RH, Rainey-Smith S, Robertson J, Rowe CC, Salvado O, Villemagne VL, Masters CL, Maruff P for the AIBL Research Group. The effect of preclinical Alzheimer’s disease on age-related changes in intelligence in cognitively normal older adults. Intelligence. 2018; 70: 22-29.

2018.42
Dehghani C, Frost S, Jayasena R, Masters CL, Kanagasingam Y. Ocular biomarkers of Alzheimer’s disease: the role of anterior eye and potential future directions. Invest Opthal Vis Sci. 2018; 58: 3554- 3563.

2018.41
Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P, for the AIBL Research Group. Superior memory reduces 8-year risk of mild cognitive impairment and dementia but not amyloid β-associated cognitive decline in older adults. Arch Clin Neuropsychol. 2018; doi: 10.1093/arclin/acy078

2018.40
Müller S, Preische O, Sohrabi H, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C, for the Dominantly Inherited Alzheimer Network (DIAN). Relationship between physical activity, cognition and Alzheimer pathology in autosomal dominant Alzheimer’s disease. Alzheimers Dement. 2018; 14: 1427-1437.

2018.39
Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P, for the AIBL Research Group. Relationship between amyloid-β positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. J Alz Dis. 2018; 65: 1313-1325.

2018.38
Harrington KD, Schembri A, Lim YY, Dang C, Ames D, Hassenstab J, Laws SM, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL,Masters CL, Maruff P and for the AIBL Research Group. Estimates of age-related memory decline are inflated by unrecognised Alzheimer’s disease. Neurobiol Aging. 2018; 70: 170-179.

2018.37
Butcher NJ, Horne MK, Mellick GD, Fowler CJ, Masters CL; AIBL research group, Minchin RF. Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease. Pharmacogenomics J. 2018; 18: 209-214.

2018.36
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM for the AIBL Research Group. Utility of an Alzheimer’s disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical Alzheimer’s disease: a prospective longitudinal study. J Alz Dis. 2018: 66; 1193-1211.

2018.35
Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O, Villemagne VL, Rowe CC, the AIBL Research Group. Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL. NeuroImage. 2018; 183: 387-393

2018.34
Baker JE, Lim YY, Jaeger J, Ames D, Lautenschlager NT, Robertson J, Piertrzak R, Snyder P, Villemagne VL, Rowe CC, Masters CL, Maruff P. Episodic memory and learning disfunction over an 18-month period in preclinical and prodromal Alzheimer’s disease. J Alz Dis. 2018; 65: 977-988.

2018.33
Bradfield NI, Ellis KA, Savage G, Maruff P, Burnham S, Darby D, Lautenschlager NT, Martins RN, Masters CL, Rainey-Smith SR, Robertson J, Rowe C, Woodward M and Ames D. Baseline amnestic severity predicts progression from amnestic mild cognitive impairment to Alzheimer disease dementia at 3 years. Alzheimer Dis Assoc Disord. 2018; 32: 190-196.

2018.32
Rainey-Smith S, Gu Y, Gardener SL, Doecke JD, Villemagne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR, Weinborn M, Ames D, Fowler C, Macaulay LS, Maruff P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Martins RN. Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Trans Psychiatry. 2018; 8: 238. doi: 10.1038/s41398-018-0293-5

2018.31
Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J,Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ, on behalf of the Dominantly Inherited Alzheimer Network. Effect of BDNF Val66Met on disease markers in Dominantly Inherited Alzheimers’ Disease. Ann Neurol. 2018; 84: 424-435.

2018.30 Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Reviews Neurol. 2018; 14: 225-236.

2018.29 Rainey-Smith SR , Mazzucchelli GN, Villemagne VL, Brown BM, Porter T, Weinborn M, Bucks RS, Milicic L, Sohrabi HR, Taddei K, Ames D , Maruff P, Masters CL, Salvado O , Rowe CC, Martins RN, Laws SM, for the AIBL Research Group. Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden. Trans Psychiat. 2018; 8: 47. doi: 10.1038/s41398-018-0094-x

2018.28
Masters CL, Gu B, Laws S, Ying Lim Y, Roberts B, Villemagne VL, and Beyreuther K. Alzheimer’s disease: towards a quantitative biological approach in describing its natural history and underlying mechanisms. In: The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms. Edited by Wolfe MS. Cambridge, Massachusetts: Academic Press; 2018: Chapter 3: p. 57-79.

2018.27
Fernando WMADB, Rainey-Smith SR, Gardener SL, Villemagne VL, Burnham SC, Macaulay SL, Brown BM, Gupta VB, Sohrabi HR, Weinborn M, Taddei K, Laws SM, Goozee K, Ames D, Fowler C, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN, for the AIBL Research Group. Associations of dietary protein and fiber intake with brain and blood amyloid-β. J Alz Dis. 2018; 61: 1589-1598.

2018.26
Martins RN, Villemagne V, Sohrabi HR, Chatterjee P, Shah TM, Verdile G, Fraser P, Taddei K, Gupta VB, Rainey-Smith SR, Hone I, Pedrini S, Lim WL, Martins I, Frost S, Gupta S, O’Bryant S, Rembach A, Ames D, Ellis K, Fuller SJ, Brown B, Gardener SL, Fernando B, Bharadwaj, P, Burnham S, Laws SM, Barron AM, Goozee K, Wahjoepramono EJ, Asih PR, Doecke JD, Salvado O, Bush AI, Rowe CC, Gandy SE, Masters CL. Alzheimer’s disease: A journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL and DIAN cohort studies. J Alz Dis. 2018; 62: 965-992.

2018.25
Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M. Rowe CC. Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA, on behalf of Alzheimer’s Disease Neuroimaging Initiative, the Australian Imaging Biomarker and Lifestyle study of ageing and the Harvard Aging Brain study. Sex, amyloid and APOEε4 and risk of cognitive decline in preclinical Alzheimer’s disease: findings from three well-charcacterized cohorts. Alzheimers Dement. 2018; 14: 1193-1203.

2018.24
Perin S, Harrington KD, Lim YY, Ellis K, Ames D, Pietrzak RH, Schembri A, Rainey-Smith S, Salvado O, Laws SM, Martins RN, Villemagne VL, Rowe CC, Masters CL, Maruff P, for the AIBL research group. Amyloid burden and incident depressive symptoms in preclinical Alzheimer’s disease. J Affect Dis. 2018; 229: 269-274.

2018.23
Weinborn M, Bucks RS, Sohrabi HR, Rainey-Smith SR, Brown BM, Gardener SL, Gozt A, Christensen D, Savage G, Laws SM, Taddei K, Maruff P, Robertson J, Ellis KA, Ames D, Masters CL, Rowe CC and Martins R for the AIBL research group. Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer’s disease, mild cognitive impairment and healthy aging: A longitudinal study. Psychological Assessment. 2018; 30: 1308-1316.

2018.22
Lim YY, Kalinowski P, Pietrzak RH, Laws SM, Burnham SC, Ames D, Villemagne VL, Fowler CJ, Rainey-Smith SR, Martins RN, Rowe CC, Masters CL, Maruff PJ. Association of β-amyloid and apolipoprotein E ε4 with memory decline in preclinical Alzheimer disease. JAMA Neurol. 2018; 75: 488-494

2018.21
Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Fowler C, Ellis E, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH and Maruff P and for the Australian Imaging, Biomarkers and Lifestyle Research Group. Trajectories of depressive and anxiety symptoms in older adults: A 6-year prospective cohort study. Int J Geriatr Psychiatry. 2018; 33: 405-413.

2018.20
Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports. 2018; 8: 2034. doi: 10.1038/s41598-018-20513-y.

2018.19
Doecke JD, Rembach A, Villemagne VL, Varhghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li Q-X, Collins S and the AIBL Research Group. Concordance between cerebrospinal fluid biomarkers with Alzheimer’s disease pathology between three independent assay platforms. J Alz Dis. 2018; 61: 169-183

2018.18
Lan J, Galindo AN, Doecke J, Fowler C, Rainey-Smith SR, Cominetti O, Dayon L. A systematic evaluation of the use of human plasma and serum for mass spectrometry-based shotgun proteomics. J Proteome Res. 2018; 17:1426-1435

2018.17
Porter T, Villemagne VL, Savage G, Millicic L, Lim YY, Maruff P, Masters CL, Ames D, Bush AI, Rainey-Smith S, Rowe CC, Groth D, Taddei K, Martins RN, Verdile G, Burnham SC, Laws SM, for the AIBL Research Group. Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease. Personalized Med Psychiatry. 2018; 7: 14-20.

2018.16
Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Reviews Neurol. 2018; 14: 225-236.

2018.15
Rainey-Smith SR , Mazzucchelli GN, Villemagne VL, Brown BM, Porter T, Weinborn M, Bucks RS, Milicic L, Sohrabi HR, Taddei K, Ames D , Maruff P, Masters CL, Salvado O , Rowe CC, Martins RN, Laws SM, for the AIBL Research Group. Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden. Trans Psychiat. 2018; 8: 47. doi: 10.1038/s41398-018-0094-x

2018.14
Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk EW … Visser JP. Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry. 2018; 75: 84–95. doi:10.1001/jamapsychiatry.2017.3391

2018.13
Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports. 2018; 8: 2034. doi: 10.1038/s41598-018-20513-y.

2018.12
Masters CL, Gu B, Laws S, Ying Lim Y, Roberts B, Villemagne VL, and Beyreuther K. Alzheimer’s disease: towards a quantitative biological approach in describing its natural history and underlying mechanisms. In: The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms. Edited by Wolfe MS. Cambridge, Massachusetts: Academic Press; 2018: Chapter 3: 57-79.

2018.11
Fernando WMADB, Rainey-Smith SR, Gardener SL, Villemagne VL, Burnham SC, Macaulay SL, Brown BM, Gupta VB, Sohrabi HR, Weinborn M, Taddei K, Laws SM, Goozee K, Ames D, Fowler C, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN, for the AIBL Research Group. Associations of dietary protein and fiber intake with brain and blood amyloid-β. J Alz Dis. 2018; 61: 1589-1598.

2018.10
Brown BM, Rainey-Smith SR, Doré V, Peiffer JJ, Burnham SC, Laws SM, Taddei K, Ames D, Masters CL, Rowe CC, Martins RN, Villemagne VL. Self-reported physical activity is associated with tau burden measured by position emission tomography. J Alz Dis. 2018; 63: 1299-1305.

2018.09
Perin S, Harrington KD, Lim YY, Ellis K, Ames D, Pietrzak RH, Schembri A, Rainey-Smith S, Salvado O, Laws SM, Martins RN, Villemagne VL, Rowe CC, Masters CL, Maruff P, for the AIBL research group. Amyloid burden and incident depressive symptoms in preclinical Alzheimer’s disease. J Affect Dis. 2018; 229: 269-274.

2018.08
Weinborn M, Bucks RS, Sohrabi HR, Rainey-Smith SR, Brown BM, Gardener SL, Gozt A, Christensen D, Savage G, Laws SM, Taddei K, Maruff P, Robertson J, Ellis KA, Ames D, Masters CL, Rowe CC and Martins R for the AIBL research group. Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer’s disease, mild cognitive impairment and healthy aging: A longitudinal study. Psychological Assessment. 2018; 30: 1308-1316.

2018.07
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K[enji], Ishii K[anzunari], Arahata Y, Iwamoto S, Ito K, , Tanaka K, Masters CL, Yanagisawa K. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018; 554: 249-254. [See also Extended Data and Supplementary Information]

2018.06
Lim YY, Kalinowski P, Pietrzak RH, Laws SM, Burnham SC, Ames D, Villemagne VL, Fowler CJ, Rainey-Smith SR, Martins RN, Rowe CC, Masters CL, Maruff PJ. Association of β-amyloid and apolipoprotein E ε4 with memory decline in preclinical Alzheimer disease. JAMA Neurol. 2018; 75: doi:10.1001/jamaneurol.2017.4325

2018.05
Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports. 2018; 8: 2034. doi: 10.1038/s41598-018-20513-y.

2018.04
Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li Q-X, Collins S and the AIBL Research Group. Concordance between cerebrospinal fluid biomarkers with Alzheimer’s disease pathology between three independent assay platforms. JAlz Dis. 2018; 61: 169-183

2018.03
Butcher NJ, Horne MK, Mellick GD, Fowler CJ, Masters CL, AIBL research group and Minchin RF. Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease. The Pharmacogenomics Journal. 2018; 18: 209-214

2018.02
Lan J, Nunez Galindo A, Doecke J, Fowler C, Rainey-Smith SR, Cominetti O, Dayon L. A systematic evaluation of the use of human plasma and serum for mass spectrometry-based shotgun proteomics. Analytical Chemistry. 2018; 17: 1426-1435

2018.01
Mito R, Raffelt D, Dhollander T, Vaughan DN, Tournier J-D, Salvado O, Brodtmann B, C Rowe CC, Villemagne VL, Connelly C. Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment, Brain. 2018; 141: 888–902. https://doi.org/10.1093/brain/awx355

2017


2017.25
Villemagne VL, Doré V, Bougeat P, Burnham S, Mulligan R, Laws S, Fripp J, Cummings T, Salvado O, Masters CL, Rowe CC. The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. J Mol Med Ther. 2017; 1: 25-32.

2017.24
Rangia P, Desmond P, Yates P, Salvado O, Bourgeat P, Fripp J, Pejoska S, Woodward M, Masters CL , Rowe CC, Villemagne VL. Focal Aβ-amyloid deposition precedes cerebral microbleeds and superficial siderosis: a case report. J Neurosci Neurol Disord. 2017; 1: 39-44

2017.23
Harrington KD, Gould E, Lim YY, Ames D, Pietrzak RH, Rembach A, Rainey-Smith S, Martins RN, Salvado O, Villemagne VL, Rowe CC, Masters CL and Maruff P for the AIBL Research Group. Amyloid burden and incident depressive symptoms in cognitively normal older adults. Int J Geriat Psychiat. 2017; 32: 455-463.

2017.22
Frost S, Robinson L, Rowe CC, Ames D, Masters CL, Taddei K, Rainey-Smith SR, Martins RN, Kanagasingam Y. Evaluation of cholinergic deficiency in preclinical Alzheimer’s disease using pupillometry. J. Opthalmol. 2017; doi.org/10.1155/2017/7935406

2017.21
Gardener SL, Rainey-Smith SR, Sohrabi HR, Weinborn M, Verdile G, Fernando WMADB, Lim YY, Harrington K, Burnham S, Taddei K, Masters CL, Macaulay SL, Rowe CC, Ames D, Maruff P, Martins RN, for the AIBL Research Group. Increased carbohydrate intake is associated with poorer performance in verbal memory and attention in an APOE genotype- dependent manner. J Alz Dis. 2017;58:193-201.

2017.20
Lim YY, Rainey-Smith S, Lim Y, Laws SM, Gupta V, Porter T, Bourgeat P, Ames D, Fowler C, Salvado O, Villemagne VL, Rowe CC, Masters CL, Zhou XF, Martins RN, Maruff P, on the behalf of the AIBL Research Group. BDNF Val66Met in preclinical Alzheimer’s disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. Int Psychogeriat. 2017. 29:1825-1834.

2017.19
Pedrini S, Gupta VB, Hone E, Doecke J, O’Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN, and the AIBL Research Group. A blood based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort. Scientific Reports. 2017; 7: 14057. doi: 10.1038/s41598-017-14020-9

2017.18
Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Martins RN, Rainey-Smith S, Robertson J, Rowe CC, Salvado O, Doré V, Villemagne VL, Snyder PJ, Masters CL, and Maruff P for the AIBL Research Group. Amyloid-β associated cognitive decline in the absence of clinical disease progression and systemic illness. Alz Dem: Assess Diag Dis Mon. 2017; 8: 156–164.

2017.17
Gupta VB, Hone E, Pedrini S, Doecke J, O’Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN and the AIBL Research Group. Altered levels of blood proteins in Alzheimer’s disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alz Dem: Diag, Assess, Dis Mon. 2017; 8: 60-72.

2017.16
Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, Diouf I, Farquharson S, Fripp J, Ames D, Doecke J, Desmond P, Ordidge R, Masters CL, Rowe CC, Maruff P, Villemagne VL, the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group, Salvado O, Bush AI. Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. Brain. 2017; 140:2112-2119. [See also Scientific Commentary: Derry PJ, Kent TA. Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer’s disease. Brain. 2017; 140; 2066-2078].

2017.15
Fandos N, Pérez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M and the AIBL Research Group. Plasma amyloid β 42/40 ratios as biomarkers for amyloid-β cerebral deposition in cognitively normal individuals. Alz Dem: Diag Asses Dis Mon. 2017; 8; 179-187.

2017.14
Gardener SL, Rainey-Smith SR, Sohrabi HR, Weinborn M, Verdile, G, Fernando WMADB, Lim YY, Harrington K, Burnham S, Taddei K, Masters CL, Macaulay SL, Rowe CC, Ames D, Maruff P, Martins RN, AIBL Research Group. Increased carbohydrate intake is associated with poorer performance in verbal memory and Attention in an APOE Genotype-Dependant Manner. J Alz Diz. 2017; 58; 193-201.Doi: 10.3233/JAD-161158.

2017.13
Lim YY, Williamson R, Laws SM, Villemagne VL, Bourgeat P, Fowler C, Rainey-Smith S, Salvado O, Martins RN, Rowe CC, Masters CL, and Maruff P, for the AIBL Research Group. Effect of APOE genotype on amyloid deposition, brain volume, and memory in cognitively normal older individuals. J Alz Dis. 2017; 58:1293-1302

2017.12
Laws SM, Gaskin S, Woodfield A, Srikanth V, Bruce D, Fraser PE, Porter T, Newsholme P, Wijesekara N, Burnham S, Doré V, Li Q-X, Maruff P, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Villemagne VL, Martins RN, Verdile G. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports 2017. 7:9766. doi: 10.1038/541598-017-09577-4

2017.11
Hollands S, Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Harrington K, Porter T, Snyder P, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Robertson J, Rowe CC, Masters CL and Maruff P, for the AIBL research group. APOE ε4 genotype, amyloid and clinical disease progression in cognitively normal older adults. J Alz Dis. 2017; 57: 411-422.

2017.10
Cardoso BR, Hare DJ, Bush AI, Li QX, Fowler CJ, Masters CL, Martins RN, Ganio K, Lothian A, Mukherjee S, Kapp EA, Roberts BR and the AIBL research group. Selenium levels in serum, red blood cells and cerebrospinal fluid of Alzheimer’s disease patients: a report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). J Alz Dis. 2017; 57: 183-193.

2017.09
Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Fowler C, Ellis E, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH and Maruff P and for the Australian Imaging, Biomarkers and Lifestyle Research Group. Trajectories of depressive and anxiety symptoms in older adults: A 6-year prospective cohort study. Int J Geriat Psych 2017. doi: 10.1002/gps.4761

2017.08
Frost S, Bhuiyan A, Offerman D, Doecke JD, Macaulay SL, Sohrabi HR, Ames D, Masters CL, Martins RN, Kanagasingam Y and the AIBL Research Group. Modulation of retinal arteriolar central reflection by APOE genotype. Curr Alz Res. 2017; 14: 916-923

2017.07
Villemagne VL, Doré V, Bourgeat P, Burnham SC, Laws S, Salvado O, Masters CL and Rowe CC. Aβ-amyloid and tau imaging in dementia. Sem Nucl Med. 2017; 47: 75-88.

2017.06
Pietrzak RH, Laws SM, Lim YY, Bender SJ, Porter T, Doecke J, Ames D, Fowler C, Masters CL, Milicic L, Rainey-Smith S, Villemagne VL, Rowe CC, Martins RN, Maruff P for the Australian Imaging, Biomarkers and Lifestyle Research Group. Plasma cortisol, brain amyloid-β, and cognitive decline in preclinical Alzheimer’s disease: A 6-year prospective cohort study. Biol Psychiat: Cog Neurosci Neuroimaging. 2017; 2: 45-52.

2017.05
Khan W, Giampietro V, Khondoker M, Faux NG, Ginestet C, Dell’Acqua F, Bouls D, Newhouse S, Dobson R, Banaschewski T, Barker GJ, Bokde ALW, Büchel C, Conrod P, Flor H, Frouin V, Garavan H, Gowland P, Heinz A, Ittermann B, Lamaître H, Nees F, Paus T, Pausova Z, Rietschel M, Smolka MN, Ströhle A, Gallinat J, Vellas B, Soininen H, Kloszewska I, Tsolaki M, Mecocci P, Spenger C, Villemagne VL, Masters CL, Muehlboeck J-S, Wahlund L-O, Schumann G, Lovestone S, Westman E, Simmons A. Alzheimer’s Disease Neuroimaging Initiative, AddNeuroMed Consortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group, and the IMAGEN consortium. A multi-cohort study of ApoE ε4 and β-amyloid effects on the hippocampus in Alzheimer’s disease, mild cognitive impairment and normal ageing. J Alz Dis. 2017; 56; 1159-1174.

2017.04 Roberts DB, Lind M, Wagen AZ, Rembach A, Frugier TJ, Li Q-X, Ryan TM, McLean CA, Doecke JD, Rowe CC, Villemagne VL, Masters CL. Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PET. Brain. 2017; 140: 1486-1498.

2017.03
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C,Tanzi R, Masters CL. A randomized exploratory molecular imaging study targeting Aβ-amyloid with a novel 8-OH quinoline in Alzheimer’s disease (The PBT2-204 IMAGINE Study). Alz Dem: Trans Res Clin Invest. 2017; 3: 622-635

2017.02
Gross AL, Hassenstab J, Johnson SC, Clark LR, Resnick SM, Kitner-Triolo M, Masters CL, Maruff P, Morris JC, Soldan A, Pettigrew C, Albert MS. A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: the preclinical AD consortium. Alz Dem: Diag Assess Dis Mon. 2017; 8: 147-155

2017.01
Cerin E, Rainey-Smith SR, Ames D, Lautenschlager NT, Macaulay L, Fowler C, Robertson JS, Rowe CC, Maruff P, Martins RN, Masters CL, Ellis KA. Associations of neighbourhood environment with brain imaging outcomes in the AIBL cohort. Alz & Dement. 2017; 13: 388-398.

2016


2016.23
Roberts BR, Doecke JD, Rembach A, Yévenes LF, Fowler CJ, McLean CA, Lind M, Volitakis I, Masters CL, Bush AI, Hare DJ, and the AIBL Research Group. Rubidium and potassium levels are altered in Alzheimer’s disease brain and blood but not in cerebrospinal fluid. Acta Neuropath Comm. 2016; 4: doi: 10.1186/s40478-016-0390-8

2016.22 Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, and Maruff P. Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease. Neurology. 2016; 86: 1635-1642

16.21 Muenchhoff J, Poljak A, Thalamuthu A, Gupta VB, Chatterjee P, Raftery M, Masters CL, Morris JC, Bateman RJ, Fagan AM, Martins RN, Sachdev PS. Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease. Sci Rep. 2016; 6: doi: 10.1038/srep29078

2016.20
François M, Fenech MF, Thomas P, Hor M, Rembach A, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, The Australian Imaging, Biomarkers and Lifestyle (AIBL) study research group. High content, multi-parameter analyses in buccal cells to identify Alzheimer’s disease. Current Alzheimer Research. 2016; 13: 787-799

2016.19
Brown BM, Rainey-Smith SR, Bucks RS, Weinborn M, Martins RN. Exploring the bi-directional relationship between sleep and beta-amyloid. Current Opinion in Psychiatry 2016; 29: 397-401

2016.18 Chong TWH, Loi SM, Lautenschlager NT, Ames D. Therapeutic advances and risk factor management: our best chance to tackle dementia? MJA 2016; 204: 91-92.

2016.17
Harrington KD, Lim YY, Ames D, Hassenstab J, Rainey-Smith S, Robertson J, Salvado O, Masters CL, and Maruff P for the AIBL Research Group. Using robust normative data to investigate the neuropsychology of cognitive aging. Arch Clin Neuropsych. 2016: 1-13.

2016.16
Heffernan AL, Chidgey C, Peng P, Masters CL, Roberts BR. The neurobiology and age-related prevalence of the ε4 allele of apolipoprotein E in Alzheimer’s disease cohorts. J Mol Neurosci. 2016; 60: 316-324.

2016.15
Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, Sperling R, Amariglio R. A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer’s disease. J Mol Neurosci. 2016; 60: 354-361.

2016.14
Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Bourgeat P, Martins RN, Salvado O, Rowe CC, Masters CL, Maruff P on behalf of the AIBL research group. Performance on the Cogstate Brief Battery is related to amyloid levels and hippocampal volume in very mild dementia. J Mol Neurosci. 2016; 60: 362:370.

2016.13
Yassi N, Desmond PM, Masters CL. Magnetic resonance imaging of vascular contributions to cognitive impairment and dementia. J Mol Neurosci. 2016; 60: 349-353.

2016.12
Baker J, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alz Dement. 2016; Doi:10.1016/j.dadm.2016.09.002.

2016.11
Albrecht MA, Masters CL, Ames D, Foster JK and the AIBL research group. Impact of mild head injury on neuropsychological performance and cognitive decline in cognitively healthy older adults: longitudinal assessment in the AIBL cohort. Frontiers in Aging Neuroscience. 2016; 8: doi: 10.3389/fnagi.2016.00105.

2016.10
Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL. Predicting Alzheimer disease from a blood-based biomarker profile: A 54 month follow up. Neurology. 2016; 87: 1093-1101.

2016.09
Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN and the AIBL Research Group. Plasma apolipoprotein J as a potential biomarker for Alzheimer’s disease: Australian Imaging Biomarkers and Lifestyle Study of aging. Alz Dementia: Diagnosis, Assessment and Disease Monitoring. 2016; 3: 18-26.

2016.08
Lim YY, , Snyder PJ, Pietrzak RH, Ukiqi A, Villemagne VL, Ames D, Salvado O, Bourgeat P, Martins RN, Masters CL, Rowe CC, Maruff P for the AIBL Research Group. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer’s disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alz Dementia. 2016; 2: 19-26.

2016.07
Brown BM, Rainey-Smith SR, Villemagne VL, Weinborn M, Bucks RS, Sohrabi HR, Laws SM, Taddei K, Macaulay L, Ames D, Fowler C, Maruff P, Masters CL, Rowe CC, Martins RN, and the AIBL Research Group. The relationship between sleep quality and brain amyloid burden. Sleep. 2016; 39: 1063-1068.

2016.06
Gu BJ, Huang X, Ou A, Rembach A, Fowler C, Avula PK, Horton A, Doecke JD, Villemagne VL, Macaulay SL, Maruff P, Fletcher EL, Guymer R, Wiley JS, Masters CL. The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study. Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease. Acta Neuropath 2016; 132: 377-389.

2016.05
Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ, Kiddle SJ, Baird AL, Sainz-Fuertes R, Leung R, Graf J, Hehir CT, Baker D, Cereda C, Bazenet C, Ward M, Thambisetty M, Lovestone S. Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J Alz Dis. 2016; 52: 561-72
2016.04
Buckley RF, Maruff P, Ames D, Bourgeat P, Martins RN, Masters CL, Rainey-Smith S, Lautenschlager N, Rowe CC, Savage G, Villemagne VL, Ellis KA, and other co-investigators in the AIBL study. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer’s disease. Alz & Dement. 2016; 12: 796 – 804.

2016.03
Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BNM, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD. Atrophy, hypometabolism and clinical trajectories in amyloid-negative Alzheimer’s disease patients. Brain. 2016; 139: 2528-2539

2016.02
Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL for the AIBL Research Group. Clinical and cognitive trajectories in cognitively elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016; 15: 1044 – 1053. [See also Commentary: Bischof GN. Alzheimer’s disease risk: amyloid versus neurodegeneration. Lancet Neurol. 2016; 15: 1000-1001.

2016.01
Zwan MD, Villemagne VL, Dore V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay L, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC, for the AIBL study. Subjective memory complaints in APOE ε4 carriers are associated with high amyloid-β burden. J Alz Dis. 2016: 49: 1115-1122.

2015


2015.33
Masters, C. L. (2015, November 8). New Prion Disease Raises Questions About Whether Alzheimer’s and Parkinson’s Could Be Infectious. The Conversation. Retrieved from http://theconversation.com/new-prion-disease-raises-questions-about-whether-alzheimers-and-parkinsons-could-be-infectious-46936

2015.32
Gardener SL, Rainey-Smith SR, Macaulay SL, Taddei K, Rembach A, Maruff P, Ellis KA, Masters CL, Rowe CC, Ames D, Keogh JB, Martins RN. Comparative analysis of the cancer council of Victoria and the online commonwealth scientific and industrial research organisation FFQ. The British Journal of Nutrition 2015; 114:1683-1693.

15.31.Thai C, Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Ames D, Ellis KA, Rainy-Smith SR, Harrington K, Martins RN, Masters CL, Rowe CC, and Maruff P, for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE epsilon4 and Is Detectable over 18-Months. PLoS One 2015; 10: e0139082. doi: 10.1371/journal.pone.0139082.

15.30.Buckley RF, Saling MM, Ellis KA, Rowe CC, Maruff P, Macaulay SL, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Ames D, on behalf of the Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. Age Ageing 2015; 44; 1012-1019.

2015.29
Rembach A, Evered LA, Li Q-X, Nash T, Vidaurre L, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Maher S, Mooney F, Farrow M, Taddei K, Rainey-Smith S, Laws SM, Macaulay L, Wilson W, Darby D, Martins R, Ames D, Collins S, Silbert B, Masters CL, Doecke JD and the AIBL Research Group. Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. Alzheimers Res Ther 2015; 7: doi:10.1186/s13195-015-0157-7.

2015.28
Poole SG, Bell JS, Jokanovic N, Kirkpatrick CM, Dooley MJ. A systematic review of medication exposure assessment in prospective cohort studies of community dwelling older australians. PLoS One 2015; doi:10.1371/journal.pone.0124247.

2015.27
Hendrix JA, Finger B, Weiner MW, Frisoni GB, Iwatsubo T, Rowe CC, Kim SY, Guinjoan SM, Sevlever G, Carrillo MC. The Worldwide Alzheimer’s Disease Neuroimaging Initiative: An update. Alzheimers Dement 2015; 11:850-859.

2015.26
Voyle N, Baker D, Burnham SC, Covin A, Zhang Z, Sangurdekar DP, Tan Hehir CA, Bazenet C, Lovestone S, Kiddle S, Dobson RJ. Blood Protein Markers of Neocortical Amyloid-beta Burden: A Candidate Study Using SOMAscan Technology. J Alzheimers Dis 2015; 46:947-961.

2015.25
Dean T & Finkel E. Blood test may be key to Alzheimer’s treatment. Cosmos. Retrieved from https://cosmosmagazine.com/life-sciences/blood-test-may-be-key-alzheimer%E2%80%99s-treatment

2015.24
Cheng L, Doecke JD, Sharples R, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe C, Macaulay SL, Masters CL, Hill AF, for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Molec Psych. 2015; 20: 118-1196.

2015.23
Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, Rembach A, Laws SM, Masters CL, Villemagne VL, Rowe CC, Maruff P, for the Australian Imaging, Biomarkers and Lifestle (AIBL) Research Group. Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging. 2015: 36; 1231-1238.

2015.22
Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P for the AIBL research group. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease. Molec Pscyh. 2015: 20; 1322-1328 [see also: Zakaib GD. Do neutrophin and ApoE together exacerbate Alzheimer’s? ALZFORUM (http://www.alzforum.org/news/research-news/do-neurotrohin-and-apoe-together-exacerbate-alzheimers). (October 10, 2014).]

2015.21
Burnham S, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins R, Maruff P, Masters C, Romano G, Rowe C, Savage G, Twyman R, Macaulay L, Narayan V, the Alzheimer’s Disease Neuroimaging Intiative and the AIBL Research Group. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal AD trials: An AIBL study. J Alz Dis. 2015: 46; 1079-1089.

2015.20
Leifert W, Nguyen T, Rembach A, Martins R, Masters CL, Ames D, Rowe CC, Macaulay SL, François M, Fenech M. Buccal cell cytokeratin 14 correlates with multiple blood biomarkers of Alzheimer’s disease risk. J Alz Dis. 2015: 48: 443-452.

2015.19
Merkel B, Steward C, Vivash L, Malpas CB, Phal P, Moffat BA, Cox KL, Ellis KA, Ames D, Cyarto E, Lai MM, Rowe CC, Sharman M, Szoeke C, Masters CL, Lautenschlager NT and Desmond P. Semi-automated hippocampal segmentation in people with cognitive impairments using an age appropriate template for registration. J Mag Res Imaging. Doi:10.1002/jmri.24966.

2015.18
Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurobiology Aging. 2015: 36; 1239-1244.

2015.17
Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton K, Pertile K, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws S, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S for the AIBL Research Group. Alzheimer disease normative CSF biomarkers validated in PET Aβ characterized subjects from the Australian Imaging, Biomarker and Lifestyle (AIBL) study. J Alz Dis. 2015: 48; 175-187.

2015.16
Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WLF, Rembach A, Rainey-Smith S, Ames D, Cobiac L, Macaulay L, Masters CL, Rowe CC, Bush AI, Martins RN and the AIBL Research Group. Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alz Res Therapy. 2015; 7: 16. Doi: 10.1186/s13195-015-0105-6.

2015.15
Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR. Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturation. ACS Chem Neurosci. 2015; 6: 398-402.

2015.14
Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, Masters CL, Ames D, Ellis KA, Rowe CC, Salvado O, Fripp J for the AIBL research group. Comparison of MR-less PiB SUVR quantification methods. Neurobiol of Aging. 2015; 36 Suppl 1: S159-S166.

2015.13
Laske C, Sohrabi HR, Frost SM, Lopez-de-Ipina K, Garrard P, Buscema M, Dauwels J, Soekadar SR, Mueller S, Linnemann C, Bridenbaugh SA, Kanagasingam Y, Martins RN, O’Bryant SE. Innovative diagnostic tools for early detection of Alzheimer’s disease. Alzheimers Dement. 2015; 11: 561-78.

2015.12
O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski J Q, Schupf N, Rissman RA, Fagan A M, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R, for the STAR-B and BbBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement. 2015; 11: 549-560.

2015.11
Buckley RF, Ellis KA, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Villemagne V, Macaulay SL, Szoeke C, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Saling MM, the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Phenomenological characterisation of memory complaints in preclinical and prodromal Alzheimer’s disease. Neuropsychology. 2015; 29: 571-581.

2015.10
Lim YY, Pietrzak RH, Bourgeat P, Ames D, Ellis KA, Rembach A, Harrington K, Salvado O, Martins RN, Snyder PJ, Masters CL, Rowe CC, Villemagne VL, Maruff P. Relationships between performance on the Cogstate Brief Battery, neurodegeneration and Aβ accumulation in cognitively normal older adults and adults with MCI. Arch Clin Neuropsych 2015; 30: 49-58.

2015.09
Watt AD, Perez KA, Ang C-S, O’Donnell P, Rembach A, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Faux NG, Masters CL, Villemagne VL, Barnham KJ. Peripheral α-defensins 1 and 2 are elevated in Alzheimer’s disease. J Alz Dis. 2015; 44: 1131-1143.

2015.08
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alz & Dem. 2015: 11; 1-15, e1-4.

2015.07
Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P for the Australian Imaging, Biomarkers and Lifestyle Research Group. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer’s disease: A multicentre, prospective cohort study. JAMA Psychiatry. 2015; 72: 284-291.

2015.06
Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Lautenschlager N, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P, for the AIBL Research Group. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alz Dis. 2015; 43: 677-686.

2015.05 Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC. Aβ imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiat. 2015; 86: 431-436.

2015.04 Albrecht MA, Szoeke C, Maruff P, Savage G, Lautenschlager N, Ellis K, Taddei K, Martins R, Masters C, Ames D, Foster JK, the AIBL Research Group. Longitudinal cognitive decline in the AIBL cohort: the role of APOE ε4 status. Neuropsychologia. 2015; 75: 411-419.

2015.03
Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early days and future perspectives. Lancet Neurol. 2015; 14: 114-124.

2015.02
Rembach A, Stingo FC, Peterson C, Vannucci M, Do K-A, Wilson WJ, Macaulay SL, Ryan TM, Martins RN, Ames D, Masters CL, Doecke JD and the AIBL Research Group. Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer’s Disease. J Alz Dis. 2015; 44: 917-925.

2015.01
Gardener SL, Rainey-Smith SR, Barnes MB, Sohrabi HR, Weinborn M, Lim YY, Harrington K, Taddei K, Gu Y, Rembach A, Szoeke C, Ellis KA, Masters CL, Macaulay SL, Rowe CC, Ames D, Keogh JB, Scarmeas N, Martins RN for the AIBL Research Group. Dietary patterns and cognitive decline in an Australian study of ageing. Molec Psych. 2015; 20: 860-866.

2014


2014.32
Chong TWH, Doyle CJ, Cyarto EV, Cox KL, Ellis KA, Ames D, Lautenschlager N and the AIBL Research Group. Physical activity program preferences and perspectives of older adults with and without cognitive impairment. Asia Pac Psychiatry. 2014; 6: 179-190.

2014.31
Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Molec Imag. 2014; 41: 816-826.

2014.30
Okamura N, Furumoto S, Fodero-Tavoletti M, Mulligan R, Harada R, Yates P, Pejoska S, Kudo Y, Masters C, Yanai K, Rowe C, Villemagne V. Noninvasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014; 137: 1762-1771.

2014.29
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014; 13: 614-629.

2014.28
Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulay SL , Ellis KA, Szoeke C, Martins RN, Rowe CC, Masters CL, Ames D, Zhang P. Genetic algorithm with logistic regression for prediction of progression of Alzheimer’s disease. BMC Bioinformatics. 2014; 15: Suppl 16: S11.

2014.27
Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Villemagne VL, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Szoeke C, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Ellis KA and the Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Autobiographical narratives relate to Alzheimer’s disease biomarkers in older adults. Int Psychogeriatrics. 2014; 26:1737-1746.

2014.26
Brown BM, Bourgeat P, Peiffer JJ, Burnham S, Laws SM, Rainey-Smith SR, Bartrés-Faz D, Villemagne VL, Taddei K, Rembach A, Bush A, Ellis KA, Macaulay SL, Rowe CC, Ames D, Masters CL, Maruff P, Martins RN for the AIBL Research Group. Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurol 2014; 83: 1345-1352.

2014.25
Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay LS, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD and the AIBL research group. An increased Neutrophil-Lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunology. 2014; 273: 65-71.

14.24 Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR. Decreased serum zinc is an effect of ageing and not Alzheimer’s disease. Metallomics: integrated biometal science. 2014; 6: 1216-1219.

2014.23
Villemagne VL, Dorѐ V, Yates P, Brown B, Mulligan R, Bourgeat P, Veljanoski R, Rainey-Smith SR, Ong K, Rembach A, Williams R, Burnham SC, Laws SM, Salvado O, Taddei K, Macaulay SL, Martins RN, Ames D, Masters CL, Rowe CC. En attendant centiloid. Advances in Research. 2014; 2: 723-729.

2014.22
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS for the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing: the Alzheimer’s Disease Neuroimaging Initiative; and the Alzheimer’s Disease Cooperative Study. The preclinical Alzheimer cognitive composite measuring amyloid-related decline. JAMA Neurol. 2014: 71: 961-970. [See also editorial: Kryscio RJ. Secondary Prevention Trials in Alzheimer Disease: The challenge of identifying a meaningful end point. JAMA Neurol 2014; doi10.1001/jamaneurol.2014.1120].

2014.21
Villemagne VL, Fodero-Tavoletti M, Yates P, Masters CL and Rowe CC. Aβ imaging in aging, Alzheimer’s disease and other neurodegenerative conditions. In: PET and SPECT in Neurology. Edited by R.A Dierckx, A. Otte, E.F.J. de Vries, A. van Waarde and K.L. Leenders. Berlin Heidelberg: Springer-Verlag; 2014: 213-254.

2014.20
Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA, for the Alzheimer’s Disease Neuroimaging Initiative, the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, and the Harvard Aging Brain Study. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurol. 2014; 82: 1760-1767.

2014.19
Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke J, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rowe C, Salvado O, Macaulay L, Masters CL, Villemagne V and the AIBL Research Group. A blood based predictor for neocortical Amyloid burden in Alzheimer’s disease: Results from the AIBL study. Mol Psychiatry. 2014; 19: 519-526.

2014.18
Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martin RN, Bush AI, Masters CL and the AIBL research group. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alz Dement 2014; 10: 53-61.

2014.17
Brodaty H, Mothakunnel A, De Vel-Palumbo M, Ames D, Ellis K, Reppermund S, Kochan NA, Savage G, Troller J, Crawford J, Sachdev PS. Influence of population versus convenience sampling on sample characteristics in studies of cognitive ageing. Ann Epidemiol. 2014; 24: 63-71.

2014.16
Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis. 2014; 40: 95-104.

2014.15
Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Harrington K, Martins RN, Masters CL, Szoeke C, Savage G, Villemagne VL, Rowe CC for the AIBL Research Group. Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimers Dement. 2014; 10: 743-751.

2014.14
Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington K, Bourgeat P, Salvado O, Bush AI, Martins RN, Masters CL, Rowe CC, Maruff P for the AIBL Research Group. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer’s disease: A preliminary study. PLoS One 2014; 9: e86498. Doi:10.1371/journal.pone.0086498.

2014.13
Yates PA, Desmond PM, Phal PM, Steward C, Szoeke C, Salvado O, Ellis KA, Martins RN, Masters CL, Ames D, Villemagne VL, Rowe CC for the AIBL research group. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014; 82: 1266-1273.

2014.12
Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, RS Mulligan, Birchall I, Harada R, Masters CL, Yanai K, Kudo Y, Rowe CC, Okamura N and Villemagne VL. Assessing THK 523 selectivity for tau deposits in Alzheimer’s disease and non-Alzheimer disease tauopathies. Alzheimers Res Ther. 2014; 6: 11.

2014.11
Moore E, Ames D, Mander AG, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis K, Bush AI, Faux NG, Martins R, Masters CL, Rowe C, Szoeke C, Watters DA, and the AIBL investigators. Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. J Alzheimers Dis. 2014; 39:661-668.

2014.10 Ellis K, Szoeke C, Bush A, Darby D, Graham P, Lautenschlager N, Macaulay L, Martins R, Maruff P, Masters C, McBride S, Rainey-Smith S, Rembach A, Robertson J, Rowe C, Savage G, Woodward M, Wilson W, Villemagne V, Zhang P, Ames D and the AIBL investigators. Rates of diagnostic transition and cognitive change at 18 month follow up among 1112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship study of Ageing (AIBL). Int Psychogeriatr. 2014; 26: 543-554.

2014.09
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chѐtelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, dela Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M and the Subjective Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alz & Dement. 2014; 10: 844-852.

2014.08
Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li Q-X, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, and Martins RN for the AIBL Research Group. Associations between gonadotropins, testosterone, and β amyloid in men at risk of Alzheimer’s Disease. Mol Psych. 2014; 19: 69-75.

2014.07
Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC for the AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain 2014; 137: 221-223.

2014.06
Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: A review of clinical, genetic, and neuroimaging associations. Front Neurol. 2014; 4: 205.

2014.05
Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Szoeke C, Ellis KA. Personal memory function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. J Alzheimers Dis. 2014; 40: 551 – 561.

2014.04
Pietrzak RH, Scott JC, Neumeister A, Lim YY, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P; the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year perspective cohort study. Br J Psychiatry. 2014; 204: 400-1.

2014.03
Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J, AIBL Research Group. MR-less surface-based amyloid assessment based on 11C PiB PET. PLOS One. 2014; 9: e84777.

2014.02
Rembach A. Alzheimer disease: the search for a blood-based biomarker for Alzheimer disease. Nat Rev Neurol. 2014; 10: 618-619.

2014.01
Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL, The AIBL Research Group, Bush AI. An anemia of Alzheimer’s disease. Mol Psychiatry. 2014; 19: 1227-1234.

2013


2013.35
Ames D, Ritchie C. Prospective cohort studies in dementia. Int Review Psychiatry. 2013; 25: 647-649.

2013.34
Szoeke CEI, Robertson JS, Rowe CC, Yates P, Campbell K, Masters CL, Ames D, Dennerstein L and Desmond P. The Women’s Healthy Ageing Project: Fertile ground for investigation of healthy participants “at risk” for dementia. International Review of Psychiatry 2013; 25: 726-737.

2013.33
Maruff P, Lim YY, Darby D, Ellis KA, Pietrzak RH, Snyder PJ, Bush AI, Szoeke C, Savage G, Ames D, Masters CL for the AIBL Research Group. Clinical utility of the CogState brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Pharma and Toxicol. 2013; 1: 30.

2013.32
Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol. 2013; 41: 11-18.

2013.31
Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am. 2013; 97: 377-398.

2013.30
Bourgeat P, Dore V, Villemagne VL, Rowe CC, Salvado O, Fripp J. MilxXplore: a web-based system to explore large imaging datasets. J Am Med Inform Assoc. 2013; 20: 1046-1052.

2013.29
Frost S, Kanagasingam Y, Sohrabi H, Bourgeat P, Villemagne V, Rowe CC, Macaulay SL, Szoeke C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN; AIBL Research Group. Pupil response biomarkers for early detection and monitoring of Alzheimer’s disease. Curr Alzheimer Res. 2013; 10: 931-939.

2013.28
Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D &Villemagne VL. Predicting Alzheimer’s disease with beta-amyloid imaging: Results from AIBL. Annals of Neurology. 2013; 74: 905-913.

2013.27
Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, Barnes J, Villemagne VL, Rowe CC, Fox NC, Ourselin S, Schott JM. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PloS One. 2013; 8: e58816.

2013.26 Villemagne VL, Rowe CC. Long night’s journey into the day: amyloid beta imaging in Alzheimer’s disease. J Alzheimers Dis. 2013; 33: S349-359.

2013.25
Sona A, Ellis KA, Ames D. Rapid cognitive decline in Alzheimer’s disease: a literature review. Int Review Psychiatry. 2013; 25: 650-658.

2013.24
Ellis KA, Rainey-Smith SR, Rembach A, Macaulay SL, Villemagne VL and the AIBL research group. Enabling a multidisciplinary approach to the study of aging and Alzheimer’s disease: An update from the AIBL study. Int Rev Psychiatry. 2013; 25: 699-710.

2013.23
Rembach A, Hare DJ, Lind M, Fowler CJ, Cherny RA, McLean C, Bush AI, Masters CL, Roberts BR. Decreased copper in Alzheimer’s disease brain is predominantly in the soluble extractable fraction. Int J Alz Disease 2013: 623241.

2013.22
Lim YY, Ellis KA, Harrington K, Pietrzak RH, Gale J, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P and the AIBL Research Group. Cognitive decline in adults with amnestic mild cognitive impairment and high A-beta amyloid: Prodromal Alzheimer’s Disease. J Alzheimers Dis. 2013; 33: 1167-1176.

2013.21
Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P for the AIBL research group. Aβ amyloid, cognition and APO E genotype in healthy older adults. Alzheimers Dement 2013; 9: 538-545.

2013.20
Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, Barnham KJ and Masters CL. Progress towards a consensus biomarker for Alzheimer’s disease: a review of peripheral based analytes. Biomark Med 2013; 7: 641-662.

2013.19
Harrington KD, Lim YY, Ellis KA, Copolov C, Darby D, Weinborn M, Ames D, Martins RN, Savage G, Szoeke C, Rowe C, Villemagne VL, Masters CL, Maruff P. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI. Int Psychogeriat. 2013; 25: 1667-1677.

2013.18
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM. Update on appropriate use criteria for Amyloid PET imaging: Dementia experts, mild cognitive impairment and education. Alzheimers Dement 2013; 9: e106-109.

2013.17
Burnham SC, Villemagne VL, Macaulay SL. The AIBL study: opening the presymptomatic window in Alzheimer disease. MJA 2013; 198:578.

2013.16
Foster JK, Albrecht MA, Savage G, Lautenschlager NT, Ellis KA, Maruff P, Szoeke C, Taddei K, Martins R, Masters CL, Ames D and the AIBL Research Group. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle study. Brain 2013; 136: 2201-2216.

2013.15
Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush A, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, and Martins RN, for the AIBL Research Group. Physical activity and amyloid-β plasma and brain levels: results from the Australian, Imaging, Biomarkers and Lifestyle Study of Ageing. Molec Psych 2013; 18: 875-881

2013.14
Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan A, Heegaard N, Hsiung G-YR, Hyman B, Iqbal K, Lachno DR, Lleό, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijick M, Verbeek MM, Zetterberg H, Blennow K; on behalf of the Alzheimer’s Association QC Program Work Group. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimer’s Dement. 2013; 9: 251-261.

2013.13
Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chételat G, Raniga P, Mulligan RS, Salvado O, Putz B, Roth K, Masters CL, Reininger CB and Rowe CC. 18F-florbetaben Aβ imaging in mild cognitive impairment. Alz Res Therapy 2013; 5: 4.

2013.12
Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stoffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush A, Masters CL, Rowe CC, Ames D, Darby D, Maruff P. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). Archives Clin Neuropsychology. 2013; 28: 320-330.

2013.11
Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O, Darby D, Snyder PJ, Bush AI, Martins RN, Masters CL, Rowe CC, Nathan PJ, Maruff P for the AIBL Research Group. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiol Aging. 2013; 34: 2457-2464.

2013.10
Buckley R, Saling M, Ames D, Lautenschlager N, Macauley SL, Martins RN, Masters CL, O’Meara T, Rowe CC, Savage G, Szoeke C, Villemagne VL, Ellis KA for the Australian Imaging Biomarkers and Lifestyle Research Group. Factors affecting subjective memory complaints in the AIBL aging study: biomarker, memory, affect and age. IntPsychogeriatr. 2013; 25: 1307-1315.

2013.09
Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselényi Z, Masters CL, Villemagne VL. Head to head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for Aβ imaging in aging and dementia. J Nucl Med 2013; 54: 880-886.

2013.08
Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetélat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O and Rowe CC. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness and memory in cognitively unimpaired individuals and in Alzheimer’s disease. JAMA Neurol 2013; 70: 903-911.

2013.07
Lim YY, Ellis KA, Harrington K, Kamer A, Pietrzak RH, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne V, Ames D, Maruff P, and the AIBL research group. Cognitive consequences of high A-beta amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer’s Disease. Neuropsychology. 2013; 27: 322-332.

2013.06
Frost S, Kanagasingam Y, Sohrabi H, Bourgeat P, Salvado O, Villemagne V, Rowe CC, Macaulay SL, Szoeke C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN, and the AIBL research group. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s Disease. Transl Psychiatry. 2013 Feb 6;3: e233.

2013.05
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12: 357-367 [See also comment: Schneider LS. Quantifying an amyloid β model for Alzheimer’s disease. Lancet Neurol 2013; 12: 327-328].

2013.04
Lim YY, Pietrzak RH, Ellis KA, Jaeger J, Harrington K, Ashwood T, Szoeke C, Martins RN, Bush AI, Masters CL, Rowe CC, Villemagne VL, Ames D, Darby D, Maruff P. Rapid decline in episodic memory in healthy older adults with high Amyloid-β. J Alz Dis. 2013; 33: 675-679.

2013.03
Carillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O’Meara T, Macauley L, Milner A, Ellis K, Maruff P, Rainey-Smith SR, Martins RN, Bain LJ, Head RJ. Research and standardization in Alzheimer’s trials: Reaching international consensus. Alzheimers Dement. 2013; 9: 160-168.

2013.02
Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P, AIBL research group. Decline in cognitive function over 18 months in healthy older adults with high A-beta amyloid. J Alzheimers Dis. 2013; 34: 861-871.

2013.01
Rembach A, Doecke J, Roberts B, Duce JA, Faux NG, Volitakis I, Trounson B, Fowler CJ, Pertile KK, Rumble BL, Varghese J, Ellis KA, Rowe CC, Martins RN, Ames D, Masters CL, Bush AI and the AIBL research group. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer’s disease. J Alzheimers Dis. 2013; 34: 171-182.

2012


2012.21
Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Villemagne VL, Rowe CC, Fripp J and the AIBL Research Group. MR-less Surface-based Amyloid estimation by subject-specific atlas selection and Bayesian fusion. Med Image ComputComput Assist Interv 2012; 15: 220-227.

2012.20
Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB, Rainey-Smith SR, Taddei K, Burnham S, Ellis KA, Szoeke C, Masters CL, Ames D, Rowe CC, Martins RN, and the AIBL research group. Intense physical activity is associated with cognitive performance in the elderly. Transl Psych. 2012 Nov 2; 2: e191.

2012.19
Gardener S, GuY, Rainey-Smith S, Keogh JB, Clifton PM, Mathieson SL, Taddei K, Mondal A, Ward VK, Scarmeas N, Barnes M, Ellis KA, Head R, Masters CL, Ames D, Macaulay L, Rowe CC, Szoeke C, Martins RN and The AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer’s disease risk in an Australian population. Transl Psychiatry. 2012 Oct 2; 2: e164.

2012.18
Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam C-P, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, for the Alzheimer’s Disease Neuroimaging Initiative and the Australian Imaging Biomarker and Lifestyle research group. Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Arch Neurol. 2012; 69:1318-1325 [see also In Reply: Laske C. Blood-based biomarkers in Alzheimer’s disease: where are we now, where have we to go? and Laws SM, Doecke J, Martins RN. In reply: “Blood-based biomarkers in Alzheimer’s disease: where are we now, where have we to go?” – Christoph Laske. Arch Neurol].

2012.17
Cyarto EV, Lautenschlager NT, Desmond PM, Ames D, Szoeke C, Salvado O, Sharman MJ, Ellis KA, Phal PM, Masters CL, Rowe CC, Martins RN and Cox KL. Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. Bio Med Central Psychiatry 2012; 12: 167.

2012.16
Villemagne VL, Furumoto S, Fodero-Travoletti MT, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N. The challenges of tau imaging. Future Neurol 2012, 7(4):409-421.

2012.15
Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P and the AIBL Research Group. Stronger effect of amyloid load than ApoE genotype on cognitive decline in healthy older adults. Neurology 2012; 79: 1645-1652.

2012.14
Fodero-Travoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dyrks T, Cappai R. In Vitro characterisation of 18F-Florbetaben, an Aβ imaging radiotracer. Nucl Med Biol 2012; 39: 1042-1048.

2012.13
Lim YY, Harrington K, Ames D, Ellis KA, Lachovitzki R, Snyder PJ, Maruff P. Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer’s disease measured using the International Shopping List Test. J ClinExpNeuropsychol 2012 ; 34: 853 – 863.

2012.12
Villain N, Chètelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL and the AIBL research group. Regional dynamics of amyloid-beta deposition in healthy elderly, Mild Cognitive Impairment and Alzheimer’s Disease: a voxelwise PiB-PET longitudinal study. Brain 2012; 135: 2126-2139.

2012.11
Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood based amyloid beta assays: The need for consensus on pre-analytical processing. J Alzheimers Dis 2012; 30: 323-336.

2012.10
Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, O’Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC. Differential diagnosis in Alzheimer’s disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. (In: Proceedings of the 10th International Conference on AD/PD 2011. Edited by Nitsch RM, Fisher A, Windisch M, Hanin I.) Neurodegen Dis 2012; 10: 161-165.

2012.09
Acosta O, Fripp J, Dore V, Bourgeat P, Favreau J-M, Chételat G, Rueda A, Villemagne VL, Szoeke C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O. Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer’s disease. J Neurosci Methods 2012; 205: 96-109.

2012.08
Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of (11)C-PiB and (18)F-florbetaben for A-beta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012; 39: 983-9.

2012.07
Head R, Ames D, Masters CL, Rowe CC, Macaulay SL, and the Australian Imaging Biomarker and Lifestyle study of Ageing. The AIBL study throwing light on amyloid-beta and Alzheimer’s disease. Med J Aust 2012; 196: 376-377.

2012.06
Chètelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC, and the Australian Imaging Biomarker and Lifestyle study of Ageing (AIBL) Research Group. Relationships between memory performances and β-amyloid deposition at different stages of Alzheimer’s disease. Neurodegener Dis 2012; 10: 141-144.

2012.05
Barber B, Ames D, Ellis K, Martins R, Masters C, and Szoeke C. Lifestyle and late life cognitive health: sufficient evidence to act now?.[Guest Editorial] IntPsychogeriatrics 2012; 24: 683-688.

2012.04
Lim YY, Ellis K, Harrington K, Ames D, Martins R, Masters C, Rowe C, Szoeke C, Darby D, Maruff P. Use of CogState brief battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. J ClinExpNeuropsychol 2012; 34: 345-58.
2012.03
Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC and the AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012; 78: 477-484.

2012.02
Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, Ikonomovic MD, Ishii K, Jack CR, Jagust WJ, Johnson KA, Koeppe RA, Lowe VJ, Masters CL, Montine TJ, Morris JC, Nordberg A, Petersen RC, Reiman EM, Selkoe DJ, Sperling RA, Van Laere K, Weiner MW, Drzezga A. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012; 39:209-219.

2012.01
Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins R, Masters C, Rowe C, Szoeke C, Taddei K, Ellis K and the AIBL research group. Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian, Imaging, Biomarker and Lifestyle (AIBL) study of ageing. International Psychogeriatrics 2012; 24: 197-204.

2011


2011.17
Leroux H, McBride S, Gibson S. On selecting a clinical trial management system for large scale, multi-centre, multi-modal clinical research study. Studies in health technology and informatics. 2018: 168; 89-95. doi: 10.3233/978-1-60750-791-8-89.

2011.16
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, IwatsuboT,Jack CR, Kaye J, Montine TJ, ParkDC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo M, Thies B, Morrson-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations of the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s and Dementia 2011; 7: 280-92.

2011.15
Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, the AIBL Research Group, Bush AI. Homocysteine, vitamin B12 and folic acid levels in Alzheimer’s disease, mild cognitive impairment and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 2011; 27: 909-22.

2011.14
Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J, Richard F, Cottel D, Berr C, Ames D, Masters, CL, Rowe CC, Szoeke C, Tzourio C, Dartigues JF, Buée L, Martins R, Amouyel P. Association of plasma Aβ peptides with blood pressure in the elderly. PLoS One 2011 April 15; 6.

2011.13
Yates PA, Sirisriro R, Villemagne VL, Farquason S, Masters CL, Rowe CC and the AIBL Research Group. Cerebral microhaemorrhage and brain Aβ amyloid in healthy ageing and Alzheimer’s disease. Neurol 2011; 77: 48 – 54.

2011.12
Mattsson N, Andreason U, Persson S, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto L, Blankenstein RA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan A, Forlenza O, Frisoni G, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovitz AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen C, Kummer M, Liu J, Lladó A, Lewczuk P, Li Q-X, Martins R, Masters CL, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine T, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen R, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski J, Tumani H, Umek R, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek M, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer’s Association external quality control program for CSF biomarkers. Alzheimer’s and Dementia2011; 7: 386–395.

2011.11
Fodero-Tavoletti MT, Villemagne VL, Rowe CC, Masters CL, Barnham KJ, Cappai R. Amyloid-β: The seeds of darkness. Int. J. Biochem Cell Biol2011; 43: 1247-51.

2011.10
Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia 2011; 49: 2384-90.

2011.09
Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor A, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 2011; 134: 1089-1100.

2011.08
Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ. Increasing the predictive accuracy of beta-amyloid blood-borne biomarkers in Alzheimer’s disease. J Alzheimers Dis 2011; 24: 47-59.
2011.07
Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, Ames D, O’Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent contribution of temporal A deposition to memory decline in the predementia phase of Alzheimer’s disease. Brain 2011; 134: 798-807.

2011.06
McBride SJ, Szoeke CEI, Good NM, Ames D, Martins RN, Masters CL, Maruff PT, Rowe CC, Savage G, Ellis KA and the AIBL Research Group. A web-based normative data tool for assessing cognitive performance in healthy older Australians. Med J Aust(Supplement) 2011; 194: 512-14.

2011.05
Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA, and the AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement GeriatrCognDisord 2011; 31:173-178.

2011.04
Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN for the AIBL Research Group. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurol 2011; 76: 1091-1098.

2011.03
Lim NK-H, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li Q-X. Investigation of matrix metalloproteinases, MMP-2 and MMP-9 in plasma reveals a decrease of MMP-2 in Alzheimer’s disease. J Alzheimers Dis2011 Jan 1; 26: 779-86.

2011.02
Ellis KA, Rowe CC, Szoeke CEI, Villemagne VL, Ames D, Chételat G, Martins RN, Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Advances in structural and molecular neuroimaging in Alzheimer’s disease. Med J Aust(Supplement) 2011; 194: 520-23.

2011.01
Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan R, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of Aβ and cognition in aging and Alzheimer’s disease. Ann Neurol 2011; 69: 181-192.

2010


2010.10
Bahar-Fuchs A, Moss S, Pike KE, Villemagne VL, Masters CL, Rowe C, Savage G. Olfactory deficits and A1 burden in AD, MCI and healthy ageing: a PiB PET Study. J Alzheimers Dis2010; 22: 1081-1087.

2010.09
Rueda A, Acosta O, Couprie M, Bourgeat P, Fripp J, Dowson N, Romero E, Salvado O. Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. J Neurosci Methods 2010; 188: 305-315.

2010.08
Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010; 133: 3349-3358.

2010.07
Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010: 31; 1275-1283.

2010.06
Lui JK, Laws SM, Li Q-X, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN for the AIBL Research Group. Plasma amyloid-β as a biomarker in Alzheimer’s Disease: The AIBL Study of Aging. J Alzheimers Dis 2010; 20; 1233-1242.

2010.05
Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC. 11C-PiB PET ABri imaging in Worster-Drought syndrome (Familial British Dementia): A case report. J Alzheimers Dis. 2010; 19: 423-428.

2010.04
Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O’Keefe GJ, Salvado O, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann Neurol2010; 67: 317-324. [See also editorial: Rabinovici GD and Roberson ED. Beyond diagnosis: what biomarkers are teaching us about the “biology of Alzheimer disease. Ann Neurol 2010; 67: 283-285.

2010.03
Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ. Blood borne amyloid-1 dimer correlates with clinical markers of Alzheimer’s disease. J Neurosci2010; 30: 6315-6322.

2010.02
Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D and the AIBL Research group. Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s & Dementia 2010; 6: 291-296.

2010.01
Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O on behalf of the AIBL Research Group. β-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.

2009


2009.09
Bates KA, Verdile G, Li Q-X, Ames D, Hudson P, Masters CL and Martins RN. Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009; 14: 469-486

2009.08
Acosta O, Bourgeat P, Fripp J, Zuluaga MA, Fripp J, Salvado O, Ourselin S. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Medical Image Analysis 2009; 13: 730-743.

2009.07
Okamura N, Fodero-Tavoletti MT, Kudo Y, Rowe CC, Furumoto S, Arai H, Masters CL, Yanai K, Villemagne VL. Advances in molecular imaging for the diagnosis of dementia. Expert Opin Med Diagn 2009; 3: 705-716.

2009.06
Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O’Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid 0-peptide deposition across different autosomal Alzheimer’s disease mutation types. Arch Neurol2009; 66: 1537-1544.

2009.05
Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G, Baxendale D, Masters CL, Rowe CC, Collins SJ. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J NeurolNeurosurgPsychiatr2009; 80: 998-1001.

2009.04
Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. In vitro characterisation of BF227 binding to -synuclein/Lewy Bodies. Eur J Pharmacol2009; 617: 54-58.

2009.03
Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li Q-X, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in AD and other dementias. J Nucl Med 2009; 50: 198-204.

2009.02
Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer’s disease and other dementias. Brain ImagBehav 2009; 3: 246-261.

2009.01
Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D and the AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. International Psychogeriatrics 2009; 21: 672-687.

2008


2008.01
Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O’Keefe G, Masters CL, Ames D, Ellis K, Maruff P, Currie J, Villemagne VL, Rowe C, Salvado O and Ourselin S. Appearance modelling of C11 PiB PET images: characterizing amyloid deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging. Neuroimage 2008; 43: 430-439

2007


2007.07
Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortés M, Culvenor JG, Li Q-X, Laughton KN, Rowe CC, Masters CL, Cappai R, Villemagne VL. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365-10371.

2007.06
Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 2007; 130: 2837-2844.

2007.05
Khalil Z, LoGuidice D, Khodr B, Maruff P, Masters C. Impaired peripheral endothelial microvascular responsiveness in Alzheimer’s disease. J Alzheimer Dis 2007; 11: 25-32.

2007.04
Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2007; 64: 1140-1144.

2007.03
Ng S, Villemagne VL, Berlangieri S, Lee S-T, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O’Keefe G, Masters CL, Rowe CC. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s Disease. J Nucl Med 2007; 48: 547-552.

2007.02
Weaver Cargin J, Maruff P, Collie A, Shafiq-Antonacci R, Masters C. Decline in verbal memory in non-demented older adults. J ClinExpNeuropsychol 2007; 29: 706-718.

2007.01
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O’Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging β-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.[See also Rowe CC, Villemagne VL, Masters CL. Correspondence: In reply to Linazasoro G. Neurology 2008; 70: 1650].

2007


2006.04
Collie A, Maruff P, Darby DG, Masters C, Currie J. The Melbourne Aging Study. In: Mild Cognitive Impairment: International Perspectives. Edited by Tuokko HA, Hultsch DF. New York: Taylor & Francis; 2006: 93-113.

2006.03
Villemagne VL, Ng S, Cappai R, Barnham KJ, Fodero-Tavoletti MT, Rowe CC, Masters CL. La LungaAttesa: Towards a molecular approach to neuroimaging and therapeutics in Alzheimer’s disease. Neuroradiol J 2006; 19: 453-474.

2006.02
Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer’s disease: Implications for neuroimaging and therapeutics. JNeurochem 2006; 97: 1700-1725.

2006.01
Weaver Cargin J, Maruff P, Collie A, Masters C. Mild memory impairment in healthy older adults is distinct from normal aging. BrainCogn 2006; 60: 146-155.

2005


2005.01
Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Imaginemoblivionis: the prospects of neuroimaging for early detection of Alzheimer’s disease. J ClinNeurosci 2005; 12: 221-230.

2004


2004.01
Maruff P, Collie A, Darby D, Weaver-Cargin J, Masters C, Currie J. Subtle memory decline over 12 months in mild cognitive impairment. Dement GeriatrCognDisord2004; 18: 342-348.

2001


2001.01
Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL, Currie J. Memory decline in healthy older people: Implications for identifying mild cognitive impairment. Neurology 2001; 56: 1533-1538.

© Copyright AIBL - Theme by Pexeto